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(0.97–1.40) for patients with idiopathic GHD (n = 41), but 
lower for patients with TS, 0.37 (−0.03 to 0.77, n = 13). 
Final height SDS was >−2 for 94 % of organic GHD, 88 % 
of idiopathic GHD and 62 % of TS patients. Mean age at 
GH start was lower for organic GHD patients, and treat-
ment duration was longer than for other groups, resulting in 
greater mean final height gain. GH-related adverse events 
occurred mainly in patients diagnosed with idiopathic 
GHD.
Conclusions Data from the Italian cohort of GeNeSIS 
showed auxological changes and safety of GH therapy 
consistent with results from international surveillance 
databases.
Keywords Pediatric GH treatment · Short stature · 
Growth · Safety · Final height
Introduction
Short stature in children is an important problem that 
should be diagnosed and managed appropriately in order 
to promote normal height [1]. Human recombinant growth 
hormone (GH) therapy was introduced in 1985 for the indi-
cation of GH deficiency (GHD), and since then, thousands 
of children with short stature have achieved improved 
height outcomes. GHD remains the main indication for GH 
therapy in children and can be due to varied etiology, with 
both congenital and acquired causes [2, 3], although for 
the majority the cause remains unknown and is termed idi-
opathic GHD. GH therapy has subsequently been approved 
in the USA and Europe for other pediatric conditions that 
result in short stature, including Turner syndrome, being 
born small for gestational age (SGA) with failure to attain 
normal growth, Prader-Willi syndrome, chronic renal 
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insufficiency, short stature homeobox-containing gene 
(SHOX) deficiency, and, in the USA but not Europe, Noo-
nan syndrome and idiopathic short stature [1, 4–11].
GH therapy in pediatric patients is generally considered 
safe, with serious adverse events reported rarely, particu-
larly with currently approved doses [12–15]. Certain spe-
cific conditions such as benign intracranial hypertension, 
scoliosis and slipped capital femoral epiphysis have been 
observed shortly after starting GH in small numbers of 
treated patients [16]. Concerns have also been raised about 
the possibility of long-term alterations in glucose metabo-
lism and an association with the occurrence of neoplasms, 
but there is little evidence for either except in patients with 
preexisting risk factors [13, 17–22].
Continued surveillance studies on efficacy and safety of 
GH therapy in children remain important, and long-term 
outcomes and safety have been documented in large inter-
national databases of GH-treated patients. These include 
the Genetics and Neuroendocrinology of Short Stature 
International Study (GeNeSIS) sponsored by Eli Lilly and 
Company, the Kabi International Growth Study (KIGS) 
sponsored by Pfizer, the National Cooperative Growth 
Study (NCGS) sponsored by Genentech and the NordiNet® 
International Outcome Study (IOS) sponsored by Novo 
Nordisk. These multinational studies provide global infor-
mation, giving an overview of the impact of GH treatment 
in children. However, there may be ethnic or regulatory dif-
ferences across and between countries that affect treatment 
uptake. These differences may involve funding, indications 
and patient ages required for treatment initiation, and fac-
tors affecting treatment outcomes, such as patient attrib-
utes that can positively or negatively affect the efficacy 
and safety of treatment. It is therefore important to identify 
country-specific data on the effects of GH therapy, which 
have currently been reported to a very limited extent. The 
objective of the current study was to evaluate the auxologi-
cal changes occurring during GH treatment in a population 
of Italian pediatric patients, based on data collected in the 
observational GeNeSIS program. As well as the Italian 
cohort overall, we have examined data within specific diag-
nostic groups where patient numbers allow.
Methods
Patient population
GeNeSIS is a prospective, multinational, open-label, post-
marketing surveillance program designed to examine the 
long-term safety and efficacy of GH (Humatrope®, Eli 
Lilly and Company, Indianapolis, USA) administered for 
short stature in children; the study also allows certain GH-
untreated cases to be followed. The multinational study is 
performed according to the ethical principles of the Decla-
ration of Helsinki and is approved by all appropriate local 
ethics review committees, with written informed consent 
for data collection, processing and publication provided by 
the parents or a legal guardian for each child according to 
national laws and regulations.
Patients enrolled in GeNeSIS were either starting 
GH treatment or already being treated with GH for the 
improvement of growth and did not present with closed 
epiphyses, although patients who had epiphyseal closure 
during participation could remain in the study. GeNeSIS 
is an observational study, and therefore, all diagnoses were 
as reported by the attending physician, and treatment deci-
sions were completely at the discretion of the participating 
investigator. However, diagnoses and treatments were to 
be performed according to standard pediatric endocrinol-
ogy practice, with GHD defined using current guidelines 
[23]. A total of 60 study centers in Italy enrolled patients 
into GeNeSIS, and the present study examined data from 
the start of the study in 1999 until data lock in September 
2012.
Study evaluations
On entry to the study, baseline values for each patient were 
recorded for chronological age, bone age, height, height 
velocity (HV), weight, and genetic target height from the 
sex-adjusted average of parental heights. Medical history, 
including diagnosis of the cause of short stature and prior 
medications, was recorded. Pubertal stage was evaluated 
according to the Tanner classification. Changes in height, 
HV and pubertal stage were determined in all study visits 
during follow-up, which occurred at least once yearly. For 
patients who reached final height during the study, final 
height and difference from genetic target height were also 
evaluated.
GeNeSIS is a multinational study, and therefore, the 
same reference data were applied across participating 
countries for calculation of standard deviation score (SDS). 
Thus, height SDS was determined according to the 2000 
US National Center for Health Statistics standards [24], 
and HV SDS was calculated using prespecified age- and 
gender-matched reference data [25].
Safety analysis was based on adverse events in all Ital-
ian patients receiving GH therapy; relationship to GH treat-
ment and severity of each event were as determined by the 
investigators. Serious adverse events were classified as 
those that resulted in death, hospitalization, persistent or 
significant disability, or congenital abnormality in offspring 
of the patient, or were considered life-threatening or sig-
nificant in the investigator’s opinion. Treatment-emergent 
adverse events were defined as events that first occurred 
or worsened in severity after initiation of GH therapy and, 
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thus, were evaluated only in patients who had at least one 
post-baseline follow-up visit. Special attention was paid 
to reports of neoplastic disease and alterations in glucose 
metabolism. All adverse events were categorized according 
to the Medical Dictionary for Regulatory Authorities (Med-
DRA), version 11.0.
Statistics
Diagnosis was evaluated for all children with sufficient 
information. Patients who were GH naïve at entry and had 
baseline and 1-year height SDS data were evaluated by 
diagnostic groups for changes in auxological parameters 
at 1 year. A subgroup, comprising patients who were GH 
naïve and had yearly height measurements for 4 years, was 
evaluated for auxological changes overall and by diagnostic 
category where patient numbers were sufficient. A further 
subgroup of patients who were either GH naïve or already 
GH-treated at entry was assessed for auxological changes 
at final or near-final height, defined as having reached one 
of the following criteria: closed epiphyses, height veloc-
ity <2 cm/year or bone age >14 years for girls or >16 years 
for boys. Data are presented as medians with first and third 
quartiles (Q1–Q3) for variables that may have a skewed 
distribution (baseline age, GH dose, time in study), as mean 
with 95 % confidence interval (CI) for efficacy-related con-
tinuous variables, and as frequency and percentage for cat-
egorical variables. Outcomes were primarily assessed from 
examination of the overlap of means and 95 % CI. Statisti-
cal analyses were conducted using SAS® 9.1.
Results
Patient disposition and characteristics
At the time of analysis, there were 711 children (58.9 % 
male, 41.0 % female) with evaluable data enrolled in GeN-
eSIS in Italy; the flow of patients through this analysis is 
shown in Fig. 1. The majority were Caucasian (90.4 %), 
with ethnic origin unspecified for 6.6 %. At GeNeSIS entry, 
27.3 % were already receiving GH and 71.6 % were GH 
naïve; 11 patients (1.5 %) did not receive GH treatment at 
any time during the study. The diagnoses associated with 
short stature leading to initiation of GH treatment are sum-
marized in Table 1 for 662 patients with sufficient evalu-
able information. The most frequent diagnosis was GHD 
(85.5 % of GH-treated total), which was reported to be idi-
opathic in 73.5 % of GHD cases and due to organic causes 
in 26.1 % of GHD cases (Table 1). The second largest diag-
nostic category resulting in GH treatment was SHOX defi-
ciency disorders (7.6 %), most commonly Turner syndrome 
(6.6 %).
Among all patients, 21.0 % were aged ≤5 years at the 
time of diagnosis, 35.3 % were aged >5 to ≤10 years, 
and 40.6 % were aged >10 to ≤15 years; a slightly higher 
proportion of females than males were in the range >5 
to ≤10 years (females 38.2 %, males 33.6 %), whereas 
a lower proportion of females were in the range >10 to 
≤15 years (38.2 %, 42.1 %). At entry to GeNeSIS, Tan-
ner stage 1 was reported for the majority of both female 
(81.3 %) and male (81.1 %) patients. At the last visit before 
data lock, 40.5 % of the male and 40.6 % of the female 
children were still prepubertal (Tanner stage 1), whereas 
pubertal stage ≥3 was reported for 46.3 % of male and 
44.8 % of female patients.
For the GH-treated patients overall, median (Q1–Q3) 
age at start of GH treatment was 9.6 (5.8–11.9) years. 
Median (Q1–Q3) starting GH dose for patients overall was 
0.23 (0.19–0.26) mg/kg/week; starting dose was higher 
for patients with Turner syndrome, 0.30 (0.26–0.34) mg/
kg/week, and for the 2 patients with chronic renal insuffi-
ciency, 0.31 (0.28–0.34) mg/kg/week, but similar across the 
other diagnostic categories. Median (Q1–Q3) follow-up in 
GeNeSIS was 2.0 (0.6–3.7) years, with follow-up ≥4 years 
for 151 patients; because 27 % had started GH before 
study entry, median total time on GH was 2.6 (1.0–4.5) 
years. Discontinuation of GH therapy was reported for 
152 patients; the reported reason was physician decision 
for 24, patient/parent decision for 24 and lack of efficacy 
for 7 patients. Discontinuation due to adverse events was 
reported for 2 patients, with death reported for one of these 
patients.
Auxological data during GH therapy
Auxological data at 1 year were available for a total of 
294 patients (184 males, 110 females) who were treatment 
naïve at baseline and received GH during the study. Of 
these, 193 had idiopathic GHD (187 isolated GHD, 6 mul-
tiple pituitary hormone deficiencies) and 60 had organic 
GHD (Table 2). Age at start of GH treatment was lower 
for the organic GHD group than for the idiopathic GHD 
group. Height SDS was similar, but deficit from target 
height was greater for those with organic GHD (Table 2). 
Responses after 1 year of GH therapy were similar for the 
two groups, and target height deficit remained greater in 
the organic GHD group. Patients with Turner syndrome 
had baseline characteristics similar to both GHD groups. 
However, although the administered GH dose was greater, 
the response at 1 year in Turner syndrome patients was less 
than for GH-deficient patients. Short stature patients born 
SGA and patients with SHOX deficiency other than Turner 
syndrome showed similar characteristics at baseline and a 
similar response at 1 year to patients with idiopathic GHD 
(Table 2).
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There were 81 patients who were GH naïve at study 
entry and had data available for at least 4 years of GH 
treatment. Changes in height SDS and HV SDS during 
4 years of GH treatment are shown in Fig. 2 for diagnostic 
groups that had sufficient evaluable information. For both 
the idiopathic GHD and organic GHD groups, there was an 
increase in HV SDS, which reduced over time as expected, 
but was sustained through 4 years of GH therapy. For 
patients with a diagnosis of Turner syndrome, there was 
a mean gain in height SDS, particularly in the first year 
of treatment, but it was lower than that for patients with 
GHD.
Auxological information was available for a total of 78 
patients (46 boys, 32 girls, GH naïve or already GH-treated 
at study entry) considered to have reached final (or near-
final) height. Data at baseline and at final height are shown 
in Table 3 for patients with idiopathic GHD, organic GHD 
and Turner syndrome. The organic GHD patients started 
GH treatment at a slightly younger mean age and were 
treated for a longer period than the idiopathic GHD group, 
Fig. 1  Flow chart showing numbers of patients in Italy available for specific analyses
Patients enrolled in GeNeSIS in Italy with 
evaluable data
(N=711)
Received GH before and/or during 
GeNeSIS and with ≥1 post-baseline visit
(alternative safety population:  treatment-
emergent adverse events)
(N=612)
With baseline and auxology data at 1 year
(N=294)
Treatment naïve at baseline and received 
GH in GeNeSIS
(N=506)a
Received GH before and/or during 
GeNeSIS (overall safety population)
(N=700)
Receiving GH at baseline
(N=194)
With baseline and auxology data at 4 years
(N=81)
With baseline and auxology data at final 
height
(N=78)
Safety populations Efficacy populations
aA total of 509 patients were originally assigned to this group; however, three patients did not receive GH treatment 
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although the final GH dose was lower for the organic GHD 
group. Mean final height SDS gain was higher for the 
organic GHD group than for the idiopathic GHD group, 
and both GHD groups had mean final height SDS close 
to target height SDS. The mean height SDS gain for the 
Turner syndrome group was lower than that for either of 
the GHD groups, and final height SDS remained below tar-
get height SDS.
Safety outcomes
There were 700 Italian children (412 males, 287 females, 1 
gender not specified) included in the overall safety analy-
sis. Mean duration of GH treatment was 3.4 years (95 % 
CI 3.2–3.7 years). One death was reported, which was of 
a 3.7-year-old boy with idiopathic isolated GHD who had 
been treated with GH for 0.8 years when he experienced 
respiratory failure, associated with a respiratory infection, 
over a period of approximately 3 months; the respiratory 
failure was considered by the investigator to be unrelated 
to GH treatment. At least one serious adverse event was 
reported for 11 (1.6 %) of the 700 patients during the study 
(Table 4). These were mostly reported among patients diag-
nosed with GHD, with no serious adverse events reported 
among the 44 Turner syndrome patients. Of the serious 
adverse events reported, 2 were classified by the investiga-
tors as related to GH treatment: an event of ketotic hypo-
glycemia in an 8.2-year-old boy with idiopathic isolated 
GHD treated with GH for 0.7 years, and a recurrence of 
craniopharyngioma in a 10.2-year-old boy who had mul-
tiple pituitary hormone deficiencies, although the diag-
nosis was not originally specified (hence, the patient was 
Table 1  Primary diagnosis and secondary level diagnoses in 662 children in Italy treated with GH for short stature
Information was as provided by the investigator and was not always provided at lower levels of diagnosis; investigator-provided diagnoses were 
assigned to a predefined hierarchical diagnostic tree to classify the primary cause of short stature and establish appropriate diagnostic groups
a Pituitary hypoplasia (55), ectopic posterior pituitary (31), pituitary aplasia (7), pituitary stalk defect (6), septo-optic dysplasia (8), other (1)
b Midline palatial defect (4)
c Craniopharyngioma (13), medulloblastoma (2), germinoma (2), glioma (1), ependymoma (1), pituitary adenoma (1)
d Noonan syndrome (3), chronic renal failure (2), inflammatory bowel disease (1), other (11)
Primary diagnosis and secondary diagnosis n (% of total) % of primary 
diagnosis
GH deficiency 566 (85.5)
 Idiopathic 416 (62.8) 73.5
  Classic 383 (57.9) 67.7
  Neurosecretory dysfunction 16 (2.4) 2.8
 Organic 148 (22.4) 26.1
  Congenital 123 (18.6) 21.7
   Abnormal pituitary developmenta 109 (16.5) 19.3
   Clinical syndromesb 4 (0.6) 0.7
   Genetic defect 4 (0.6) 0.7
   Other CNS malformations 2 (0.3) 0.4
  Acquired 25 (3.8) 4.4
   Intracranial tumorc 20 (3.0) 3.5
   Cranial irradiation 3 (0.5) 0.5
   Histiocytosis 1 (0.2) 0.2
   Other 1 (0.2) 0.2
SHOX deficiency syndromes 50 (7.6)
  Turner syndrome 44 (6.6) 88.0
  Léri-Weill syndrome 5 (0.8) 10.0
  Other diagnosis 1 (0.2) 2.0
Other causes of short stature or reduced linear growth 23 (3.5)
  Genetic defect 6 (0.9) 26.1
  Otherd 17 (2.6) 73.9
Small for gestational age 20 (3.0)
Idiopathic short stature 2 (0.3)
Other defects of GH axis (bioinactive GH) 1 (0.2)
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not included in a specific diagnostic group). Craniophar-
yngioma recurred after treatment with GH for 2.9 years, 
although an earlier recurrence in the patient was reported 
prior to starting GH. Adverse events were reported as the 
reason for discontinuation for two patients. One was the 
patient who experienced the fatal event of respiratory fail-
ure. The second was an event of impaired glucose toler-
ance, identified from an oral glucose tolerance test, in a 
13.1-year-old boy after 2.5 years of GH treatment for idi-
opathic GHD.
Among 612 GH-treated patients with at least one post-
baseline study visit, 130 (21.2 %) had at least one treat-
ment-emergent adverse event reported (Table 4). Of these, 
14 (2.3 %) patients experienced events considered by the 
investigators to be GH-related. The GH-related events 
occurred mainly in patients with a diagnosis of idiopathic 
GHD. No GH-related treatment-emergent events were 
reported in the 42 patients with Turner syndrome and at 
least one follow-up visit. The most frequent specific treat-
ment-emergent adverse event considered related to GH 
therapy was headache (in 3 patients [0.5 %]), followed by 
arthralgia (2 patients [0.3 %]) and impaired fasting glu-
cose (2 patients [0.3 %]). In addition, six patients (1.0 %) 
experienced metabolism and nutritional disorders, such 
as obesity and alterations in glucose levels, considered 
related to GH treatment. Specific neoplastic events were 
reported for 3 patients; these were two girls with Turner 
syndrome who experienced melanocytic nevi, considered 
unrelated to GH treatment, and the boy with craniopharyn-
gioma recurrence.
Table 2  Patient characteristics and auxological data at baseline and after 1 year of GH treatment, for patients who were GH treatment naïve at 
study entry and had at least 1 year of follow-up, by primary diagnostic category
Data show mean (95 % CI); patient numbers are for those with height SDS at baseline and 1 year, but not all patients had all other information
NA no available data, SDS standard deviation score, SGA short for gestational age
a 68.4 % male
b 61.7 % male
c 40.0 % male
d 50.0 % male
e Height SDS minus target height SDS
Idiopathic GHD 
(n = 193)a
Organic GHD 
(n = 60)b
Turner syndrome 
(n = 16)
SHOX deficiency 
(n = 5)c
SGA (n = 8)d
Baseline
 Age (years) 9.8 (9.3–10.3) 7.9 (6.7–9.1) 9.0 (7.1–10.8) 8.6 (6.4–10.8) 9.9 (7.4–12.4)
 Bone age SDS −2.18 (−2.38 to 
−1.99)
−2.02 (−2.49 to 
−1.54)
−1.54 (−2.40 to 
−0.68)
NA −1.18 (−2.45 to 0.09)
 Height velocity (cm/
year)
4.83 (4.12 to 5.55) 5.37 (4.32 to 6.43) 3.50 (2.18 to 4.83) NA 3.99 (1.97 to 6.01)
 Height velocity SDS −1.24 (−1.57 to 
−0.91)
−1.05 (−1.61 to 
−0.49)
−2.75 (−4.39 to 
−1.11)
NA −1.28 (−2.22 to 
−0.34)
 Height SDS −2.40 (−2.51 to 
−2.30)
−2.55 (−2.86 to 
−2.24)
−2.30 (−2.59 to 
−2.01)
−2.74 (−3.77 to 
−1.71)
−2.91 (−3.45 to 
−2.38)
 Target height SDS 
deficite
−1.40 (−1.53 to 
−1.27)
−2.14 (−2.53 to 
−1.75)
−2.01 (−2.40 to 
−1.63)
−1.37 (−1.84 to 
−0.89)
−1.49 (−2.23 to 
−0.74)
 GH dose (mg/kg/
week)
0.23 (0.22–0.24) 0.23 (0.21–0.25) 0.31 (0.27–0.35) 0.23 (0.21–0.26) 0.23 (0.19–0.27)
 Stimulated peak GH 
(µg/l)
6.43 (5.38–7.47) 6.25 (4.59–7.91) NA NA 15.14 (10.96–19.33)
Year 1
 Height velocity (cm/
year)
8.84 (8.51–9.17) 9.25 (8.49–10.00) 7.43 (6.24–8.62) 7.25 (5.30–9.21) 8.17 (7.12–9.21)
 Height velocity SDS 2.30 (2.04–2.57) 2.42 (1.83–3.02) 1.40 (0.67–2.12) 1.98 (−0.13 to 4.09) 1.63 (0.92–2.35)
 Height SDS −1.89 (−2.00 to 
−1.77)
−1.86 (−2.11 to 
−1.61)
−1.96 (−2.30 to 
−1.61)
−2.27 (−3.49 to 
−1.06)
−2.52 (−3.18 to 
−1.87)
 Height SDS gain 0.55 (0.50–0.60) 0.70 (0.52–0.88) 0.32 (0.15–0.48) 0.46 (0.18–0.74) 0.41 (0.29–0.53)
 Target height SDS 
deficite
−0.88 (−1.03 to 
−0.74)
−1.44 (−1.78 to 
−1.09)
−1.67 (−2.16 to 
−1.19)
−0.90 (−1.49 to 
−0.31)
−1.08 (−1.88 to 
−0.29)
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Discussion
The effects of GH therapy at 1–4 years of treatment and 
at final height were studied in a country-specific cohort of 
pediatric patients treated for short stature. The data exam-
ined were for children in Italy entered in the GeNeSIS sur-
veillance program. At study entry, mean height SDS was 
below −2, overall and for each of the diagnostic groups, 
and height SDS was below the target defined from paren-
tal heights. GH therapy reduced the height deficit at the 
assessments within the first few years of treatment and at 
final height for patients in individual diagnostic categories, 
with no adverse event concerns observed.
The primary diagnosis associated with short stature 
was GHD for the majority of the children (85.5 %), with 
the next most common being SHOX deficiency including 
Turner syndrome (7.6 %). The percentage of patients with 
GHD in Italy was higher than in the global GeNeSIS pop-
ulation (63.8 %), which used the same definition of GHD 
[23], although within the GHD diagnosis the proportions 
with idiopathic (73.5 %) and organic (26.1 %) causes were 
comparable to those in the global population (77.7 and 
22.0 %, respectively). In contrast, the proportion of patients 
with SHOX deficiency in Italy was lower than in the global 
study population (11.7 %). It should be noted that the 
global GeNeSIS population included 13.0 % of patients 
with idiopathic short stature, which is not an approved indi-
cation for GH therapy in Europe and would, therefore, have 
influenced the proportions of patients in the other diagnosis 
groups.
The patients with organic GHD were younger at start of 
GH treatment than those with idiopathic GHD. Mean HV, 
height SDS and gain in height SDS were similar for the 
two GHD groups over the first year through to 4 years of 
treatment. However, for patients with available data at final 
height, duration of GH treatment was longer and mean gain 
in height SDS was greater for the organic GHD group than 
the idiopathic GHD group, suggesting that age at treat-
ment start and duration of treatment may have influenced 
final height. The present results are in agreement with other 
reports that height gain is affected by factors including age 
at start of GH treatment and baseline target height deficit 
[26–29].
At final height, both GHD diagnostic groups had height 
SDS close to target height, even though the baseline target 
height deficit was greater for the organic group than the idi-
opathic GHD group. A final height SDS greater than −2 
was achieved in 94 % of patients with organic GHD and 
88 % of patients with idiopathic GHD. Interestingly, for 
patients who reached final height, the GH dose per body 
weight was lower for the organic GHD group than for the 
idiopathic GHD group. The greater response with lower 
dose in the organic GHD group relative to the idiopathic 
Fig. 2  Change in height SDS a, gain in height SDS from baseline 
b, and change in height velocity c, by duration of GH treatment, for 
patients with idiopathic GH deficiency (GHD, n = 54), organic GHD 
(n = 15) or Turner syndrome (n = 9), who were GH treatment naïve 
at study entry and had at least 4 years of follow-up
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GHD group was contrary to reports that response is greater 
with a higher dose [3, 28, 29], although others have also 
found that GH dose was not a predictor of adult height 
[27]. However, the difference in dose may reflect the more 
severe deficiency seen in the organic GHD group compared 
with the idiopathic GHD patients, and the corresponding 
better response to GH replacement.
In the Turner syndrome group, HV increased from 
3.50 cm/year before GH start to 7.43 cm/year in the first 
treatment year, similar to previously published results [30]. 
A mean gain in height SDS was seen, but this was less than 
for either GHD group at all time points evaluated. How-
ever, the mean age at which GH was initiated was relatively 
high and similar to that in the idiopathic GHD group. Early 
intervention for short stature, before the age of 4 years, has 
been reported to provide a better response [4, 31]. A slightly 
higher mean GH dose of 0.05 mg/kg/day (=0.35 mg/kg/
week) has been used in some other studies of Turner syn-
drome [4, 5, 31]; however, lower doses of 0.23–0.26 mg/
kg/week have also been utilized [30]. Administered dose 
varies widely, and the aim is to provide an effective dose 
that is well tolerated and without increased risk of adverse 
events [6, 13]. Final height SDS remained below target 
height, with a mean deficit of −1.49 SDS, although a final 
height SDS above −2 was achieved in 62 % of patients in 
the Turner syndrome group, who were treated for a mean 
of 5.1 years. These figures were very similar to a previous 
report where 62 % of Turner syndrome patients treated for 
at least 3 years had a final height SDS >−2, compared with 
40 % when the treatment duration was only 1 year [32].
Although the number of patients in the Italian GeN-
eSIS cohort was not as large as for multinational databases, 
adverse events, overall and for specific diagnostic catego-
ries, as documented by the investigators, did not present 
any new concerns and were consistent with the known 
profile for pediatric GH treatment [13, 14]. This finding 
is important, because a recent Delphi survey showed that 
Italian pediatric and adult endocrinologists follow cur-
rent guidelines and continue or reinstitute GH treatment 
in patients with confirmed GHD in the transitional period 
from adolescence to early adulthood [33], potentially pro-
longing the duration of GH administration. In the Turner 
syndrome group, no serious adverse events were identified 
and there were no GH-related treatment-emergent events. 
However, there were two reports of melanocytic nevi, 
which were considered by the investigators to be unrelated 
to GH therapy; melanocytic nevi are a common dermato-
logical finding genetically associated with Turner syndrome 
irrespective of GH treatment [15, 34, 35]. Other studies 
have also reported very few adverse events in GH-treated 
Table 3  Characteristics and auxological data at baseline and at final (or near-final) height for patients with idiopathic isolated GH deficiency 
(GHD), organic GHD or Turner syndrome, who were either GH treated or GH naïve at study entry
Data show mean (95 % confidence intervals), except final height SDS >−2, which shows percentage of patients
NA no available data, SDS standard deviation score
a 70.7 % male
b 77.8 % male
c Baseline height SDS minus target height SDS
d Final height SDS minus target height SDS
Idiopathic GHD (n = 41)a Organic GHD (n = 18)b Turner syndrome (n = 13)
Baseline
 Age 11.1 (9.9–12.4) 9.3 (6.7–11.9) 10.3 (8.7–11.9)
 Height SDS −2.04 (−2.27 to −1.82) −2.60 (−3.43 to −1.77) −2.38 (−2.73 to −2.03)
 Target height SDS deficitc −1.36 (−1.63 to −1.10) −1.98 (−2.92 to −1.04) −1.87 (−2.28 to −1.47)
 Body weight (kg) 35.1 (30.5–39.7) 28.4 (19.2–37.7) 30.0 (23.1–37.0)
 GH dose (mg/kg/week) 0.23 (0.22–0.25) 0.17 (0.13–0.22) 0.30 (0.25–0.35)
 Stimulated peak GH (µg/l) 5.15 (4.19–6.10) 3.23 (1.57–4.88) NA
Final height
 Age 16.8 (16.3–17.2) 17.7 (16.8–18.6) 16.3 (15.5–17.1)
 Height SDS −0.86 (−1.12 to −0.60) −0.60 (−1.09 to −0.11) −2.01 (−2.46 to −1.56)
 Height SDS gain 1.19 (0.97–1.40) 2.00 (1.27–2.73) 0.37 (−0.03 to 0.77)
 Target height SDS deficitd −0.17 (−0.41 to 0.07) 0.02 (−0.58 to 0.62) −1.49 (−2.09 to −0.90)
 GH duration (years) 5.38 (4.22–6.54) 8.19 (5.89–10.49) 5.10 (2.91–7.30)
 Body weight (kg) 59.7 (55.6–63.8) 65.4 (58.1–72.7) 50.3 (45.5–55.1)
 Final GH dose (mg/kg/week) 0.21 (0.19–0.23) 0.13 (0.09–0.17) 0.26 (0.23–0.29)
 Final height SDS >−2 (%) 88 % 94 % 62 %
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patients with Turner syndrome [4, 30, 31], although head-
ache, intracranial hypertension and slipped capital femoral 
epiphysis occurred more frequently in GH-treated children 
with Turner syndrome than in those with idiopathic GHD 
[16]. One death was documented, which was due to res-
piratory failure and unrelated to GH treatment. There was 
also one discontinuation in relation to impaired glucose tol-
erance, which is known to be associated with GH therapy 
[15, 17, 18].
Because of the observational nature of GeNeSIS, new 
patients were added to the database over time, which meant 
that the number of patients with long-term data was less 
than for short-term therapy. Thus, only major diagnostic 
categories could be assessed at 4 years and at final height, 
which was a limitation. All information entered in the 
database was at the discretion of the investigators; thus, not 
all information for each patient was available, and informa-
tion for untreated control patients was insufficient for com-
parison. We also did not have sufficient data concerning 
birth details (e.g., birth weight and length), genetic testing 
results and use of hormone replacement therapies that may 
have affected final height of the children in our study. Nev-
ertheless, we are not aware of any other reports of auxology 
of Italian GH-treated children and believe that the results 
can be considered as representative of GH therapy in stand-
ard endocrine practice in Italy.
In conclusion, data from the Italian cohort of GeNeSIS 
provided auxological and safety results for GH therapy 
that were consistent with those from other clinical trials 
and international surveillance databases. Height gains were 
Table 4  Serious adverse events and treatment-emergent adverse events reported in all Italian GH-treated patients and in those diagnosed with 
idiopathic and with organic GH deficiency (GHD) who had at least one post-baseline visit
a Calculated for the total modified safety population (all 700 GH-treated patients, the 416 patients with idiopathic GHD and the 148 patients 
with organic GHD)
b Treatment-emergent adverse events occurring in ≥0.5 % of patients overall. Individual terms are MedDRA preferred terms and are as coded 
by investigators at each site. Multiple terms may therefore have been selected from when classifying an event
c Site did not provide distinction between primary, secondary and tertiary events
Patients reporting adverse events, n (% of N)
All patients (N = 612) Idiopathic GHD (N = 358) Organic GHD (N = 135)
Serious adverse eventsa 11 (1.6) 5 (1.2) 4 (2.7)
 Serious adverse events considered GH-related* 2 (0.3) 1 (0.2) 0
Treatment-emergent adverse eventsb 130 (21.2) 65 (18.2) 42 (31.1)
 Headache 12 (2.0) 8 (2.2) 2 (1.5)
 Hypothyroidismc 7 (1.1) 2 (0.6) 3 (2.2)
 Hypogonadismc 6 (1.0) – 4 (3.0)
 Secondary adrenal insufficiency 6 (1.0) – 6 (4.4)
 Varicella 5 (0.8) 3 (0.8) 2 (1.5)
 Scoliosis 5 (0.8) 1 (0.3) 4 (3.0)
 Secondary hypothyroidism 4 (0.7) – 4 (3.0)
 Ear infection 4 (0.7) 2 (0.6) 1 (0.7)
 Pharyngitis 4 (0.7) 3 (0.8) 1 (0.7)
 Influenza 4 (0.7) 4 (1.1) –
 Primary hypothyroidism 3 (0.5) 1 (0.3) 2 (1.5)
 Adrenal insufficiency 3 (0.5) – 3 (2.2)
 Abdominal pain 3 (0.5) 1 (0.3) 1 (0.7)
 Diarrhea 3 (0.5) 1 (0.3) 1 (0.7)
 Pyrexia 3 (0.5) 2 (0.6) 1 (0.7)
 Bronchitis 3 (0.5) 1 (0.3) 2 (1.5)
 Urinary tract infection 3 (0.5) 1 (0.3) 2 (1.5)
 Tonsillitis 3 (0.5) 2 (0.6) 1 (0.7)
 Blood thyroid-stimulating hormone increased 3 (0.5) 1 (0.3) –
 Hypoglycemia 3 (0.5) 1 (0.3) 2 (1.5)
 Urticaria 3 (0.5) 1 (0.3) 2 (1.5)
Adverse events considered GH-related 14 (2.3) 11 (3.1) 2 (1.5)
Adverse events not considered GH-related/unknown 116 (19.0) 54 (15.1) 40 (29.6)
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observed in the first year of GH treatment through to attain-
ment of final height. Mean height gain was more pronounced 
in patients with idiopathic or organic GHD than in girls with 
Turner syndrome, and patients with GHD achieved a mean 
final height that was very similar to target height. Patients 
with organic GHD started GH treatment at a younger age 
than patients with other diagnoses and were treated for 
longer, resulting in the largest gains in final height.
Acknowledgments GeNeSIS is sponsored by Eli Lilly and Com-
pany. We would like to thank all of the patients in the study and their 
families, the investigators involved in GeNeSIS in Italy, and Eli Lilly 
and Company for financial support and for conducting the statistical 
analysis of data from Italy. We would also like to thank Dr Peter Bates 
(Cambridge Medical Writing Services, UK) and Caroline Spencer 
(Rx Communications, Mold, UK) for help in the preparation of the 
manuscript. The Italian investigators involved in GeNeSIS were as 
follows: Franco Antoniazzi (Department of Life Sciences and Repro-
duction, Pediatric Clinic, University of Verona); Luciano Beccaria 
(Pediatric Department, Hospital of Lecco); Sergio Bernasconi (Pedi-
atric Department, University of Parma); Domenico Caggiano (Unit 
of Endocrinology and Metabolism, University Hospital of Salerno); 
Manuela Caruso-Nicoletti (Pediatric Department, University of Cat-
ania); Alessandra Catucci (University Hospital OORR of Foggia); 
Francesco Chiarelli (Pediatric Department, University of Chieti); 
Stefano Cianfarani (Department of Systems Medicine, ‘Tor Vergata’ 
University, Rome); Anna Rita Colucci (Unit of Human Genetics, San 
Giuseppe Moscati Hospital, Avellino); Francesca De Rienzo (Unit of 
Pediatrics, Department of Medical Sciences, University of Piemonte 
Orientale, Novara); Raffaele Di Pumpo (Unit of Pediatrics, University 
Hospital OORR of Foggia); Alessandra Di Stasio (Pediatric Depart-
ment, Hospital of Civitanova Marche); Giovanni Farello (Pediatric 
Clinic, University of L’Aquila); Leonardo Felici (Pediatric Depart-
ment, United Hospitals, Marche Nord, Pesaro-Fano); Pasquale Femi-
ano (Sant’Anna and San Sebastiano AORN Hospital, Caserta); Luigi 
Garagantini (Pediatric Department, Hospital of Treviglio, Bergamo); 
Claudia Giavoli (Endocrine Unit, Department of Clinical Sciences 
and Community Health, Foundation IRCCS Ca’ Granda Hospital, 
University of Milan); Nella Augusta Greggio (Pediatric Department, 
University of Padova); Laura Guazzarotti (Pediatric Department, Uni-
versity of Milan, Luigi Sacco Hospital, Milan); Daniela Larizza (Pedi-
atric Department, University of Pavia, IRCCS Foundation Policlinico 
San Matteo, Pavia); Maria Rosaria Licenziati (Pediatric Department, 
AORN Santobono-Pausilipon Hospital, Naples); Antonella Lonero 
(Pediatric Department, Hospital of Bari); Maria Cristina Maggio 
(Pediatric Department, University of Palermo); Alberto Marsciani 
(Pediatric Department, Hospital of Rimini); Patrizia Matarazzo (Pedi-
atric Endocrinology, Regina Margherita Children’s Hospital, Turin); 
Laura Mazzanti (Department of Medical Genetics, S.Orsola-Malpighi 
University Hospital, University of Bologna); Beatrice Messini (Pedi-
atric Department, USL2, Foligno); Flavia Napoli (Pediatric Endocrine 
Unit, IRCCS Children’s Hospital Gaslini, Genova); Anna Maria Pas-
quino (Pediatric Department, University La Sapienza, Rome); Laura 
Perrone (Department of Women, Children and of General and Spe-
cialized Surgery, Second University of Naples); Sabrina Pilia (Pedi-
atric Department, Microcitemico Hospital, Cagliari); Alba Pilotta 
(Endocrinology, Diabetes and Human Genetics Department, Pediat-
ric Clinic of Brescia); Marzia Piran (Pediatric Department, Univer-
sity of Insubria, Varese); Gabriella Pozzobon (Pediatric Department 
San Raffaele Hospital, Milan); Barbara Predieri (Pediatric Depart-
ment, University of Modena and Reggio Emilia, Modena); Michele 
Sacco (Pediatric Department, IRCCS Casa Sollievo della Sofferenza, 
San Giovanni Rotondo); Mariacarolina Salerno (Pediatric Section, 
Department of Translational Medical Sciences, University of Naples 
Federico II, Naples); Antonina Tirendi (Pediatric Department, Carlo 
Poma Hospital, Mantova); Graziamaria Ubertini (Endocrinology 
and Diabetic Unit, IRCCS Bambino Gesù Hospital, Rome); Silvia 
Vannelli (Auxology Unit, Regina Margherita Children’s Hospital, 
Turin); Malgorzata Wasniewska (Pediatric Department, University of 
Messina); Maria Zampolli (Pediatric Department, S. Anna Hospital, 
Como); Martina Zanotti (Pediatric Department, S. Maria della Scal-
etta Hospital, Imola); and Gianvincenzo Zuccotti (Pediatric Depart-
ment, University of Milan, Luigi Sacco Hospital, Milan).
Funding The GeNeSIS study is funded by Eli Lilly and Company.
Compliance with ethical standards 
Conflict of interest The GeNeSIS study was supported by Eli Lilly 
and Company. Alessandra Vottero is an employee of Eli Lilly and 
Company Limited. Marco Cappa, Lorenzo Iughetti, Sandro Loche and 
Mohamad Maghnie have participated on the SHOX advisory board for 
Eli Lilly, and Mohamad Maghnie was a member of the GeNeSIS Inter-
national Advisory Board.
Open Access This article is distributed under the terms of the 
Creative Commons Attribution 4.0 International License (http://crea-
tivecommons.org/licenses/by/4.0/), which permits unrestricted use, 
distribution, and reproduction in any medium, provided you give 
appropriate credit to the original author(s) and the source, provide a 
link to the Creative Commons license, and indicate if changes were 
made.
References
 1. Haymond M, Kappelgaard AM, Czernichow P, Biller BM, Takano 
K, Kiess W, Global Advisory Panel Meeting on the Effects of 
Growth Hormone (2013) Early recognition of growth abnormali-
ties permitting early intervention. Acta Paediatr 102:787–796
 2. Audi L, Fernandez-Cancio M, Camats N, Carrascosa A (2013) 
Growth hormone deficiency: an update. Minerva Endocrinol 
38:1–16
 3. Ranke MB (2010) Clinical considerations in using growth 
hormone therapy in growth hormone deficiency. Endocr Dev 
18:83–91
 4. Linglart A, Cabrol S, Berlier P, Stuckens C, Wagner K, de Ker-
danet M, Limoni C, Carel JC, Chaussain JL, French Collabora-
tive Young Turner Study Group (2011) Growth hormone treat-
ment before the age of 4 years prevents short stature in young 
girls with Turner syndrome. Eur J Endocrinol 164:891–897
 5. Blum WF, Ross JL, Zimmermann AG, Quigley CA, Child CJ, 
Kalifa G, Deal C, Drop SL, Rappold G, Cutler GB Jr (2013) GH 
treatment to final height produces similar height gains in patients 
with SHOX deficiency and Turner syndrome: results of a multi-
centre trial. J Clin Endocrinol Metab 98:E1383–E1392
 6. Kappelgaard AM, Laursen T (2011) The benefits of growth hor-
mone therapy in patients with Turner syndrome, Noonan syn-
drome and children born small for gestational age. Growth Horm 
IGF Res 21:305–313
 7. Deal CL, Tony M, Höybye C, Allen DB, Tauber M, Christiansen 
JS, 2011 Growth Hormone in Prader-Willi Syndrome Clinical 
Care Guidelines Workshop Participants (2013) Growth hormone 
research society workshop summary: consensus guidelines for 
recombinant growth hormone therapy in Prader-Willi syndrome. 
J Clin Endocrinol Metab 98:E1072–E1087
 8. Jung H, Rosilio M, Blum WF, Drop SL (2008) Growth hormone 
treatment for short stature in children born short for gestational 
age. Adv Ther 25:951–978
677J Endocrinol Invest (2016) 39:667–677 
1 3
 9. Wu Y, Cheng W, Yang XD, Xiang B (2013) Growth hormone 
improves growth in pediatric renal transplant recipients—a sys-
temic review and meta-analysis of randomized controlled trials. 
Pediatr Nephrol 28:129–133
 10. Bacchetta J, Harambat J, Cochat P, Salusky IB, Wesseling-Perry 
K (2012) The consequences of chronic kidney disease on bone 
metabolism and growth in children. Nephrol Dial Transplant 
27:3063–3071
 11. Deodati A, Cianfarani S (2011) Impact of growth hormone ther-
apy on adult height of children with idiopathic short stature: sys-
tematic review. Br Med J 342:c7157
 12. Sävendahl L, Maes M, Albertsson-Wikland K, Borgström B, 
Carel JC, Henrard S, Speybroeck N, Thomas M, Zandwijken 
G, Hokken-Koelega A (2012) Long-term mortality and causes 
of death in isolated GHD, ISS, and SGA patients treated with 
recombinant growth hormone during childhood in Belgium, 
the Netherlands, and Sweden: preliminary report of 3 countries 
participating in the EU SAGhE study. J Clin Endocrinol Metab 
97:E213–E217
 13. Carel JC, Ecosse E, Landier F, Meguellati-Hakkas D, Kague-
lidou F, Rey G, Coste J (2012) Long-term mortality after recom-
binant growth hormone treatment for isolated growth hormone 
deficiency or childhood short stature: preliminary report of the 
French SAGhE study. J Clin Endocrinol Metab 97:416–425
 14. Bell J, Parker KL, Swinford RD, Hoffman AR, Maneatis T, 
Lippe B (2010) Long-term safety of recombinant human growth 
hormone in children. J Clin Endocrinol Metab 95:167–177
 15. Clayton PE, Cowell CT (2000) Safety issues in children and 
adolescents during growth hormone therapy—a review. Growth 
Horm IGF Res 10:306–317
 16. Darendeliler F, Karagiannis G, Wilton P (2007) Headache, idi-
opathic intracranial hypertension and slipped capital femoral epi-
physis during growth hormone treatment: a safety update from 
the KIGS database. Horm Res 68(suppl 5):41–47
 17. Child CJ, Zimmermann AG, Scott RS, Cutler GB Jr, Battelino 
T, Blum WF, GeNeSIS International Advisory Board (2011) 
Prevalence and incidence of diabetes mellitus in GH-treated chil-
dren and adolescents: analysis from the GeNeSIS observational 
research program. J Clin Endocrinol Metab 96:E1025–E1034
 18. Cutfield WS, Wilton P, Bennmarker H, Albertsson-Wikland K, 
Chatelain P, Ranke MB, Price DA (2000) Incidence of diabetes 
mellitus and impaired glucose tolerance in children and adoles-
cents receiving growth-hormone treatment. Lancet 355:610–613
 19. Pekic S, Popovic V (2013) GH therapy and cancer risk in hypo-
pituitarism: what we know from human studies. Eur J Endocrinol 
169:R89–R97
 20. Woodmansee WW, Zimmermann AG, Child CJ, Rong Q, 
Erfurth EM, Beck-Peccoz P, Blum WF, Robison LL, GeNeSIS 
and HypoCCS International Advisory Boards (2013) Incidence 
of second neoplasm in childhood cancer survivors treated with 
GH: an analysis of GeNeSIS and HypoCCS. Eur J Endocrinol 
168:565–573
 21. Wilton P, Mattsson AF, Darendeliler F (2010) Growth hormone 
treatment in children is not associated with an increase in the 
incidence of cancer: experience from KIGS (Pfizer International 
Growth Database). J Pediatr 157:265–270
 22. Patterson BC, Chen Y, Sklar CA, Neglia J, Yasui Y, Mertens A, 
Armstrong GT, Meadows A, Stovall M, Robison LL, Meacham 
LR (2014) Growth hormone exposure as a risk factor for the 
development of subsequent neoplasms of the central nervous 
system: report from the Childhood Cancer Survivor Study. J Clin 
Endocrinol Metab 99:2030–2037
 23. Growth Hormone Research Society (2000) Consensus guidelines 
for the diagnosis and treatment of growth hormone (GH) defi-
ciency in childhood and adolescence: summary statement of the 
GH Research Society. J Clin Endocrinol Metab 85:3990–3993
 24. Ogden CL, Kuczmarski RJ, Flegal KM, Mei Z, Guo S, Wei R, 
Grummer-Strawn LM, Curtin LR, Roche AF, Johnson CL (2002) 
Centers for Disease Control and Prevention 2000 growth charts 
for the United States: improvements to the 1977 National Center 
for Health Statistics version. Pediatrics 109:45–60
 25. Preece MA (1994) Evaluation of growth and development. In: 
Holliday MA, Barratt TM, Avner ED, Kogan BA (eds) Pediat-
ric nephrology, 3rd edn. Williams and Wilkins, Baltimore, pp 
378–396
 26. Lee PA, Germak J, Gut R, Khutoryansky N, Ross J (2011) 
Identification of factors associated with good response to 
growth hormone therapy in children with short stature: results 
from the ANSWER Program®. Int J Pediatr Endocrinol. 
doi:10.1186/1687-9856-2011-6
 27. de Ridder MA, Stijnen T, Hokken-Koelga AC (2007) Prediction 
of adult height in growth-hormone-treated children with growth 
hormone deficiency. J Clin Endocrinol Metab 92:925–931
 28. Ranke MB, Lindberg A, Price DA, Darendeliler F, Albertsson-
Wikland K, Wilton P, Reiter EO, KIGS International Board 
(2007) Age at growth hormone therapy start and first-year 
responsiveness to growth hormone are major determinants of 
height outcome in idiopathic short stature. Horm Res 68:53–62
 29. Vosahlo J, Zidek T, Lebl J, Riedl S, Frisch H (2004) Validation 
of a mathematical model predicting the response to growth hor-
mone treatment in prepubertal children with idiopathic growth 
hormone deficiency. Horm Res 61:143–147
 30. Baxter L, Bryant J, Cave CB, Milne R (2007) Recombinant 
growth hormone for children and adolescents with Turner syn-
drome. Cochrane Database Syst Rev 1:CD003887
 31. Hughes IP, Choong CS, Harris M, Ambler GR, Cutfield WS, 
Hofman PL, Cowell CT, Werther G, Cotterill A, Davies PS, Aus-
tralasian Paediatric Endocrine Group (APEG) (2011) Growth 
hormone treatment for turner syndrome in Australia reveals that 
younger age and increased dose interact to improve response. 
Clin Endocrinol 74:473–480
 32. Ross J, Lee PA, Gut R, Germak J (2011) Impact of age and dura-
tion of growth hormone therapy in children with Turner syn-
drome. Horm Res Paediatr 76:392–399
 33. Aimaretti G, Attanasio R, Cannavò S, Nicoletti MC, Castello R, 
Di Somma C, Garofalo P, Iughetti L, Loche S, Maghnie M, Maz-
zanti L, Saggese G, Salerno M, Tonini G, Toscano V, Zucchini S, 
Cappa M (2015) Growth hormone treatment of adolescents with 
growth hormone deficiency (GHD) during the transition period: 
results of a survey among adult and paediatric endocrinologists 
from Italy. Endorsed by SIEDP/ISPED, AME, SIE, SIMA. J 
Endocrinol Investig 38:377–382
 34. Brazzelli V, Larizza D, Martinetti M, Martinoli S, Calcaterra V, 
De Silvestri A, Pandolfi R, Borroni G (2004) Halo nevus, rather 
than vitiligo, is a typical dermatologic finding of Turner’s syn-
drome: clinical, genetic, and immunogenetic study in 72 patients. 
J Am Acad Dermatol 51:354–358
 35. Wyatt D (1999) Melanocytic nevi in children treated with growth 
hormone. Pediatrics 104:1045–1050
